INDIANAPOLIS, Oct. 6, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will showcase results from the ixekizumab
clinical development program during the 24th European
Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, Oct. 7-11.
Ixekizumab is the company's investigational medicine for the
treatment of moderate-to-severe plaque psoriasis.
A total of 13 presentations, including a late-breaker oral
presentation on Saturday, Oct. 10,
will report results on the investigational medicine's efficacy,
safety and patient-reported outcomes.
"For those with moderate-to-severe psoriasis, this chronic
disease can affect many facets of their daily lives, including
physical and emotional well-being, professional careers and
personal relationships," said David
Ricks, Lilly senior vice president, and president, Lilly
Bio-Medicines. "The data to be presented provide further evidence
about ixekizumab's potential, if approved, to help more people
achieve clear skin and improve their quality of life."
Data to be presented include:
Oral
Presentations:
Thursday, Oct. 8,
2015, 1:15-3:45 p.m. CEST:
Session FC03, Location: B3M1-4
- Safety and Tolerability of Ixekizumab: Analysis of Malignancies
in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis
[Presenter: Strober, B.]
Saturday, Oct. 10, 2015,
8:00-11:15 a.m. CEST: Late-Breaker
Session, Location: C1M4
- Safety Profile of Ixekizumab, an Anti-Interleukin-17A
Monoclonal Antibody, in Chronic Plaque Psoriasis Patients after at
Least Three Years of Open-Label Treatment [Presenter: Lebwohl,
M.]
Oral Poster Presentation:
Thursday, Oct. 8, 2015, 11:20-11:30 a.m. CEST: Session OP01, Location:
Interactive e-Poster Area
- Evaluation of Ixekizumab in Patients with Psoriasis and
Psoriatic Arthritis: Results of a Pooled Analysis of Three Phase 3
Studies in Moderate-to-Severe Psoriasis [Presenter: Gottlieb,
A.]
Poster Presentations:
Wednesday, Oct. 7 to Sunday, Oct. 11, 2015
- Efficacy of Ixekizumab in Patients with Plaque Psoriasis – With
and Without Previous Exposure to Biologic Therapies: Results at
Weeks 12 and 60 from UNCOVER-1 [Lead author: Gerdes, S.]
- Impact of Ixekizumab Treatment on Fingernail Psoriasis: Results
from UNCOVER-1 [Lead author: Guenther, L.]
- The Impact of Ixekizumab Treatment on Health-Related Quality of
Life in Patients with Moderate-to-Severe Psoriasis: Results from
UNCOVER-1 [Lead author: Augustin, M.]
- Impact of Ixekizumab on Psoriasis Itch Severity and Other
Patient-Reported Outcomes: Results from UNCOVER-1 [Lead author:
Kimball, A.]
- Complete Resolution of Psoriasis is Associated with Greater
Improvements in Itch and Health-Related Quality of Life: An
Analysis from UNCOVER-1 [Lead author: Reich, K.]
- Safety and Tolerability of Ixekizumab: Analysis of Neutropenia
in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis
[Lead author: Strober, B.]
- Safety and Tolerability of Ixekizumab: Analysis of Infections
in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis
[Lead author: Papp, K.]
- Impact of Ixekizumab Treatment on Sexual Function in
Moderate-to-Severe Psoriasis Patients: 12-Week Results from
UNCOVER-1 [Lead author: Guenther, L.]
- Impact of Ixekizumab Treatment on Work Productivity in Patients
with Moderate-to-Severe Plaque Psoriasis: Results from UNCOVER-1
[Lead author: Armstrong, A.]
- Psychosocial Burden of Chronic Plaque Psoriasis Assessed in an
Online Survey [Lead author: Cather, J.]
About ixekizumab
Ixekizumab is a monoclonal antibody
with high affinity and specificity that binds to and neutralizes
the pro-inflammatory cytokine interleukin-17A (IL-17A). In
psoriasis, IL-17A plays a major role in driving excess keratinocyte
(skin cell) proliferation and activation. Ixekizumab does not bind
to cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. Ixekizumab
is administered via subcutaneous injection (under the skin).
Ixekizumab is also in clinical development for the treatment of
psoriatic arthritis.
About the UNCOVER Studies
The UNCOVER studies are
double-blind, multicenter, Phase 3 studies evaluating more than
3,800 patients with moderate-to-severe psoriasis in 18
countries. UNCOVER-1 compared the safety and efficacy of different
dosing regimens of ixekizumab to placebo after 12 weeks and 60
weeks of treatment. The UNCOVER-2 and -3 studies assigned patients
to receive either placebo, etanercept (50 mg twice a week) or
ixekizumab (80 mg every two or four weeks) for 12 weeks, following
a 160 mg starting dose.
About Eli Lilly and Company
Lilly is a global health
care leader that unites caring with discovery to make life better
for people around the world. We were founded more than a century
ago by a man committed to creating high-quality medicines that meet
real needs, and today we remain true to that mission in all our
work. Across the globe, Lilly employees work to discover and bring
life-changing medicines to those who need them, improve the
understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
P-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about ixekizumab as a potential treatment for
moderate-to-severe plaque psoriasis and reflects Lilly's current
belief. However, as with any pharmaceutical product, there are
substantial risks and uncertainties in the process of development
and commercialization. Among other things, there can be no
guarantee that future study results will be similar to the results
to date or that ixekizumab will receive regulatory approvals. For
further discussion of these and other risks and uncertainties, see
Lilly's most recent Form 10-K and Form 10-Q filings with the United
States Securities and Exchange Commission. Except as required by
law, Lilly undertakes no duty to update forward-looking statements
to reflect events after the date of this release.
|
|
Refer
to:
|
Tim Coulom;
tim.coulom@lilly.com; 317-771-2241 (media)
|
|
Philip
Johnson; johnson_philip_l@lilly.com; 317-655-6874
(investors)
|
|
|
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-to-showcase-data-for-investigational-psoriasis-treatment-at-24th-european-academy-of-dermatology-and-venereology-congress-300154894.html
SOURCE Eli Lilly and Company